Neurotoxic astrocytes express the d-serine synthesizing enzyme, serine racemase, in Alzheimer's disease

• Published in: Neurobiology of disease Vol. 130; p. 104511
• Main Authors: Balu, Darrick T., Pantazopoulos, Harry, Huang, Cathy C.Y., Muszynski, Kevin, Harvey, Theresa Lynn, Uno, Yota, Rorabaugh, Jacki M., Galloway, Claire R., Botz-Zapp, Christian, Berretta, Sabina, Weinshenker, David, Coyle, Joseph T.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.10.2019; Elsevier
• Subjects: Alzheimer Disease - enzymology; Alzheimer Disease - pathology; Animals; Astrocytes - enzymology; Complement C3; Death associated protein kinase; Disease Models, Animal; Entorhinal cortex; Entorhinal Cortex - enzymology; Extrasynaptic; Glial fibrillary acidic protein; Hippocampus; Hippocampus - enzymology; Humans; N-methyl-d-asparate receptor; Racemases and Epimerases - metabolism; Rats; Rats, Transgenic; Tg-F344AD; AD; Glial fibrillary acidic protein; Complement C3; DAPK; Tg-F344AD; GFAP; C3; N-methyl-d-asparate receptor; Extrasynaptic; Entorhinal cortex; Death associated protein kinase; NMDAR; Hippocampus; SR
• ISSN: 0969-9961; 1095-953X; 1095-953X
• DOI: 10.1016/j.nbd.2019.104511

Although β-amyloid plaques are a well-recognized hallmark of Alzheimer's disease (AD) neuropathology, no drugs reducing amyloid burden have shown efficacy in clinical trials, suggesting that once AD symptoms emerge, disease progression becomes independent of Aβ production. Reactive astrocytes are another neuropathological feature of AD, where there is an emergence of neurotoxic (A1) reactive astrocytes. We find that serine racemase (SR), the neuronal enzyme that produces the N-methyl-d-aspartate receptor (NMDAR) co-agonist d-serine, is robustly expressed in A1-reactive neurotoxic astrocytes in the hippocampus and entorhinal cortex of AD subjects and an AD rat model. Furthermore, we observe intracellular signaling changes consistent with increased extra-synaptic NMDAR activation, excitotoxicity and decreased neuronal survival. Thus, reducing neurotoxic d-serine release from A1 inflammatory astrocytes could have therapeutic benefit for mild to advanced AD, when anti-amyloid strategies are ineffective. •Serine racemase synthesizes d-serine, a potent co-agonist at NMDA receptors.•In Alzheimer's disease, abundant reactive astrocytes express serine racemase.•Serine racemase–positive reactive astrocytes express A1-type neurotoxic markers.•TgF344-AD rats show increased activation of extrasynaptic NMDA receptors.•Thus, astrocytic d-serine may promote neuronal degeneration in Alzheimer's disease.